中国现代医生2026，Vol.64Issue(9)：47-51,5.DOI:10.3969/j.issn.1673-9701.2026.09.010
奈玛特韦/利托那韦影响COVID-19患者肝肾功能的真实世界研究
Real-world study on the effects of Nirmatrelvir/Ritonavir on liver and kidney function in COVID-19 patients
摘要
Abstract
Objective The purpose of this study is to explore the actual effects of Nirmatrelvir/Ritonavir treatment on liver and kidney function in coronavirus disease 2019(COVID-19)patients,in order to provide scientific basis for clinical treatment and ensure the safety of medication for patients.Methods Collect clinical data of COVID-19 patients treated with Nirmatrelvir/Ritonavir at Minzu Hospital of Guangxi Zhuang Autonomous Region from October 2022 to February 2025.Perform subgroup analysis based on the patient's liver and kidney function before treatment.Using t-test,chi square test,and non-parametric test to compare the differences in liver and kidney function indicators between patients before treatment and 3,7,14,and 21 days after treatment.Results A total of 106 COVID-19 patients receiving treatment with Nirmatrelvir/Ritonavir were included.Among them,there were 65 male patients and 41 female patients.In terms of liver function monitoring,subgroup analysis showed that the levels of gamma-glutamyl transferase in patients with normal liver function were significantly increased at 14 and 21 days after treatment compared to before treatment(P<0.05).In patients with mild liver injury,the level of aspartate aminotransferase after 3 days of treatment was significantly lower than before treatment(P<0.05).In terms of renal function monitoring,in group with 30ml/(min·1.73m2)<estimated glomerular filtration rate(eGFR)≤60ml/(min·1.73m2),the blood urea nitrogen(URea)levels after 7 days of treatment were significantly lower than before treatment(P<0.05).In group of 60ml/(min·1.73m2)<eGFR≤90ml/(min·1.73m2),serum creatinine(Creat)decreased after 7 days of treatment compared to before treatment(P<0.05).In eGFR>90ml/(min·1.73m2)group,the URea level of patients significantly decreased after 14 days of treatment compared to before treatment,and the difference was statistically significant(P<0.05).Conclusion Nirmatrelvir/Ritonavir has good liver and kidney safety for COVID-19 patients.After weighing the pros and cons,COVID-19 patients with liver and kidney dysfunction may consider using Nirmatrelvir/Ritonavir for treatment,and liver and kidney function monitoring should be conducted during medication.However,the impact of Nirmatrelvir/Ritonavir on patients with severe liver and kidney dysfunction still needs further clarification.关键词
奈玛特韦/利托那韦/COVID-19/肝功能/肾功能Key words
Nirmatrelvir/Ritonavir/COVID-19/Liver function/Renal function分类
医药卫生引用本文复制引用
曾尚勇,陆海鹏,吕聪,李嘉乐,黄小理..奈玛特韦/利托那韦影响COVID-19患者肝肾功能的真实世界研究[J].中国现代医生,2026,64(9):47-51,5.基金项目
广西壮族自治区卫生健康委员会科研课题(Z-F20231699) （Z-F20231699）
